Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.9652W HIGH $16.93
Volume
25.72 K
Value Traded
10.45 M
Short % Float
23.82%
-7.1%Week
-10.44%1 Month
+3.17%3 Month
+29.46%6 Month
-69.24%5 Year
-78.5%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
701.88 M
EPS (TTM)
-3.24
P/E Ratio
-
Ent. Value
290.56 M
Total Shares
55.24 M
Float Shares
50.42 M
Insiders
8.73%
Institutions
99.56%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
FDMT Catalyst Timeline
Dated clinical, regulatory and corporate events for 4D Molecular Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for 4D Molecular Therapeutics, Inc.
233Total events
11Upcoming
75Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲First Patient Dosed4D-150Trial
First patients enrolled in 4SIGHT Phase 3 trial of 4D-150 in DME
diabetic macular edema (DME)source ↗
▲Trial Initiation4D-150Trial
4DMT initiates 4SIGHT Phase 3 trial of 4D-150 in DME
diabetic macular edema (DME)source ↗
▲Long Term Data4D-150Clinical Data
Updated 2-year data from SPECTRA Part 1 in DME
diabetic macular edema (DME)source ↗
▲Oral Presentation4D-150Presentation
PRISM Phase 2b 2-year data presented at ASRS
wet age-related macular degenerationsource ↗
▲Full Results4D-150Clinical Data
Positive 2-Year Efficacy and Safety Data from PRISM Phase 2b
wet age-related macular degenerationsource ↗
◆Enrollment Milestone4D-150Trial
Final patient randomization expected for 4FRONT-2
wet age-related macular degenerationsource ↗
▲Debt Royalty FinancingCorporate
Strategic credit facility agreement with Hercules Capital for up to $200 million
▲Enrollment Complete4D-150Trial
Enrollment completed for 4FRONT-2 Phase 3 trial of 4D-150 in wet AMD
wet age-related macular degenerationsource ↗
◆Full Results4D-150Clinical Data
2-year Phase 2b data from PRISM trial expected in mid-2026
wet age-related macular degenerationsource ↗
▲Enrollment Complete4D-150Trial
4FRONT-2 enrollment completed
wet age-related macular degenerationsource ↗
▲Full Results4D-150Clinical Data
2-Year data cutoff May 18, 2026
wet age-related macular degenerationsource ↗
▲Long Term Data4D-150Clinical Data
4DMT reports 2-year data from SPECTRA trial of 4D-150 in DME
diabetic macular edema (DME)source ↗
▲Enrollment Complete4D-150Trial
4FRONT-1 randomization completed (N=523)
wet age-related macular degenerationsource ↗
▲Enrollment Complete4D-150Trial
Enrollment completed for 4FRONT-1 Phase 3 trial of 4D-150 in wet AMD
wet age-related macular degenerationsource ↗
▲Enrollment Complete4D-150Trial
4FRONT-1 enrollment completed
wet age-related macular degenerationsource ↗
◆Enrollment Complete4D-150Trial
4FRONT-1 Phase 3 trial enrollment completion expected in Q1 2026
wet age-related macular degenerationsource ↗
◆Full Results4D-150Clinical Data
2-year SPECTRA Phase 1/2 data for DME expected
diabetic macular edemasource ↗
◆Trial Initiation4D-710Trial
AEROW Phase 1/2 clinical trial and program update expected
cystic fibrosissource ↗
◆Quarterly Update4D-710Corporate
Program update for 4D-710 Phase 2 expected
cystic fibrosis lung diseasesource ↗
▲Interim Analysis4D-710Trial
Positive interim clinical data from 4D-710 AEROW Phase 1 trial
cystic fibrosis lung diseasesource ↗
●Oral Presentation4D-710Presentation
Corporate webcast to discuss AEROW Phase 1 interim data
cystic fibrosis lung diseasesource ↗
◆Trial Initiation4D-150Trial
APAC clinical sites for 4FRONT-2 expected to open by end of year
wet age-related macular degenerationsource ↗
◆Interim Analysis4D-710Trial
Interim safety and efficacy data from AEROW Phase 1 expected
cystic fibrosis lung diseasesource ↗
▲Full Results4D-710Clinical Data
Positive long-term interim results from AEROW Phase 1/2 trial (data cutoff Dec 1, 2025)
cystic fibrosis lung diseasesource ↗
▲Trial Initiation4D-150Trial
4D-150 4FRONT Phase 3 trials ongoing
wet age-related macular degenerationsource ↗
▲Partnership / License4D-710Corporate
Equity investment from Cystic Fibrosis Foundation for 4D-710
cystic fibrosissource ↗
▲Partnership / License4D-150Corporate
Exclusive license agreement with Otsuka for 4D-150 in APAC region
wet age-related macular degenerationsource ↗
▲Full Results4D-150Clinical Data
Positive long-term safety and efficacy data with 1.5-2 years follow-up from PRISM trial
wet age-related macular degenerationsource ↗
▲Management ChangeCorporate
Julie Clark promoted to CMO; Liansheng Zhu joined as SVP Biometrics
▼Equity OfferingCorporate
Pricing of $100 million offering of common stock and pre-funded warrants
▲Full Results4D-150Clinical Data
Positive interim 1.5- to 3.5-year data from Phase 1/2 PRISM trial in wet AMD
wet age-related macular degenerationsource ↗
▲Enrollment Update4D-150Trial
Phase 3 4FRONT trials continue to enroll ahead of initial projections
wet age-related macular degenerationsource ↗
▲Partnership / License4D-150Corporate
Exclusive license agreement with Otsuka for 4D-150 in Asia-Pacific
wet age-related macular degeneration, diabetic macular edemasource ↗
◆Oral PresentationPresentation
Management to participate in panel discussions at Chardan's 9th Annual Genetic Medicines Conference
▲Partnership / LicenseCorporate
CF Foundation provides up to $11M additional funding and technical support for 4D-710
▲Partnership / License4D-710Corporate
Equity investment from Cystic Fibrosis Foundation up to $11M
cystic fibrosis lung diseasesource ↗
▼Equity Offering4D-710Corporate
Equity investment from CF Foundation of up to $11 million
cystic fibrosis lung diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How FDMT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | 4D-150 (PRISM) | Phase 2b data readout | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C47 / 100
Pipeline Score
$191M
Pipeline Value
Overvalued
Valuation Signal
5
Drugs Scored
0.3x
rNPV / MCap
Top 24%
Micro Cap(rank 159 of 658)
Percentile Rank
4D Molecular Therapeutics, Inc. carries a moderate pipeline score (47/100), with $532M risk-adjusted pipeline value, led by 4D-150 in Macular Neovascularization Secondary to Age-Related Macular Degeneration (Phase 3), across $62B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4D-150 Monoclonal antibodyNCT06864988 | Macular Neovascularization Secondary to Age-Related Macular Degeneration | Phase 3 | ACTIVE NOT_RECRUITING | 480 | Jun 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every FDMT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| 4D-150 RMAT | diabetic macular edema (DME) | Phase 3 | 2026-09-28 | favorable safety profile; durable vision and anatomic improvements; clinically meaningful treatment burden reductionRead More | 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DMERead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kirn DavidDirector, Officer (See Remarks) | Sell | -58,061 709,425 held | $12.92 | 10/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in FDMT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.6 % (20 %) | 67.16 M | 5.05 M |
FDMT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How FDMT ranks across every disease it competes in
Competitive Position is a premium feature
See how FDMT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialFDMT News
FDMT▼ -5.5%on this news
4DMT to Host Investor Day on October 21, 2026
4D Molecular Therapeutics (FDMT) will host an Investor Day on October 21, 2026, in New York City. The event will include presentations and discussions led by retinal experts on the company's lead product, 4D-150, which targets VEGF-driven retinal diseases. Registration for the event is available online, and a webcast will be archived for future viewing.
Read more →FDMT4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
4D Molecular Therapeutics has initiated the 4SIGHT Phase 3 trial for 4D-150, targeting diabetic macular edema (DME). The trial will evaluate the drug's effectiveness compared to aflibercept in treatment-naïve patients. Positive results from previous trials highlight 4D-150's safety and potential to reduce treatment burden significantly. The company aims to address the unmet needs in retinal disease treatment.
Read more →FDMT4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics announced the granting of 96,000 Restricted Stock Units to seven new non-executive employees as part of its 2025 Employment Inducement Award Plan. This move aims to attract talent to support the company's ongoing development of disease-targeted therapeutics. The lead product candidate, 4D-150, is currently in Phase 3 development for wet age-related macular degeneration.
Read more →FDMT4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics (FDMT) announced its participation in several upcoming investor conferences in September 2026. The conferences include the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Morgan Stanley Global Healthcare Conference. The company is focused on developing disease-targeted therapeutics, with its lead product candidate, 4D-150, currently in Phase 3 development for wet age-related macular degeneration.
Read more →FDMT4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics reported its Q2 2026 financial results, highlighting the completion of enrollment for its Phase 3 trials of 4D-150 for wet AMD. The company presented positive long-term data from the PRISM Phase 2b trial and announced plans to initiate a Phase 3 trial for diabetic macular edema in Q3 2026. A strategic credit facility was secured to support operations through 2028.
Read more →FDMT4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
4D Molecular Therapeutics announced positive results from the PRISM Phase 2b trial of 4D-150, a gene therapy for wet AMD. The two-year data showed sustained visual acuity and significant reductions in treatment burden. The therapy was well tolerated, with no new safety concerns reported. This trial positions 4D-150 as a promising candidate for future Phase 3 studies.
Read more →FDMT4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
4D Molecular Therapeutics (FDMT) announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists in Montreal from July 15-18, 2026. The presentation will focus on their lead product candidate, 4D-150, which is in Phase 3 development for treating wet age-related macular degeneration. This therapy aims to provide sustained delivery of anti-VEGF biologics, significantly reducing treatment frequency for patients.
Read more →FDMT▲ +11%on this newsshared move
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
4D Molecular Therapeutics has entered into a strategic credit facility agreement with Hercules Capital for up to $200 million. This non-dilutive capital is expected to bolster the company's financial position and support the development of its lead product candidate, 4D-150, currently in Phase 3 for wet AMD and DME. The initial drawdown of $20 million has already been completed, with additional funds available upon achieving specific milestones.
Read more →FDMT▲ +11%on this newsshared move
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
4D Molecular Therapeutics has completed global enrollment for its Phase 3 clinical trial, 4FRONT-2, evaluating the efficacy of 4D-150 in treating wet age-related macular degeneration. The trial saw over-enrollment, with final patient randomization expected by Q3 2026. Topline data from the trial is anticipated in H2 2027, marking a significant step in addressing the treatment burden associated with wet AMD.
Read more →FDMT4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics (FDMT) reported its Q1 2026 financial results, highlighting the completion of randomization for its Phase 3 clinical trial of 4D-150 in wet age-related macular degeneration. The company anticipates topline data from this study in H1 2027 and plans to complete enrollment for its 4FRONT-2 trial by H2 2026. A strong cash reserve of $458 million is projected to sustain operations into the latter half of 2028, while R&D expenses have notably increased due to ongoing trial commitments. With significant data expected in the coming years, the company aims to advance its clinical pipeline despite current losses increasing compared to previous quarters.
Read more →FDMT4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics (Nasdaq: FDMT) reported its full-year financial results for 2025, highlighting successful developments in its clinical trials and financial stability. The company completed enrollment in the Phase 3 4FRONT-1 trial for wet AMD ahead of schedule, with topline data anticipated in the first half of 2027. Financially, 4DMT holds $514 million in cash, enough to extend operations into the latter half of 2028. The company also formed a strategic partnership with Otsuka, which is expected to provide substantial funding for ongoing development activities.
Read more →About 4D Molecular Therapeutics, Inc.
Headquarters5858 HORTON STREET #455, EMERYVILLE, CA, 94608
BIOPHARMAWATCH ELITE PLUS
Trade the next FDMT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime